- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Formycon AG (FYB)
Formycon AG stock price live, this page displays ETR FYB stock exchange data. View the FYB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Formycon AG real time stock price chart below.
What Is the Formycon AG Stock Price Today?
The Formycon AG stock price today is 18.50.
What Is the Stock Symbol for Formycon AG?
The stock symbol for Formycon AG is "FYB."
What Stock Exchange Does Formycon AG Trade On?
Formycon AG is listed and trades on the Xetra stock exchange.
Is Formycon AG a Good Stock to Buy?
Determining whether Formycon AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FYB quote. (ISIN: DE000A1EWVY8)
What Is the Formycon AG Stock Price Today?
The Formycon AG stock price today is 18.50.
What Is the Stock Symbol for Formycon AG?
The stock symbol for Formycon AG is "FYB."
What Stock Exchange Does Formycon AG Trade On?
Formycon AG is listed and trades on the Xetra stock exchange.
Is Formycon AG a Good Stock to Buy?
Determining whether Formycon AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FYB quote. (ISIN: DE000A1EWVY8)
Currency in EUR
18.50
-0.66(-3.44%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.50
19.40
52 wk Range
15.80
26.95
FYB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.5019.40
52 wk Range
15.8026.95
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
FYB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
39.67
Upside
+114.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 39.67
(+114.41% Upside)
Formycon AG Earnings Call Summary for Q2/2026
- H1 2026 revenue nearly tripled year-over-year; adjusted EBITDA improved to minus EUR 6.9M from minus EUR 19.2M in H1 2025.
- FYB206 Keytruda biosimilar generated over 40% of H1 revenue; FYB202 Avastin biosimilar revenues more than tripled on royalties and milestones.
- Management confirmed full-year 2026 guidance; expects H2 revenue growth driven by FYB202 U.S. distribution and European market expansion.
- Cash fell to EUR 51.8M from EUR 68.8M at year-end 2025; company plans to add 2-3 pipeline molecules in H2 2026.
- Shares down 0.31% to $19.10; stock trades 29% below 52-week high amid competitive biosimilar market and uneven revenue timing risks.
Last Updated: 08/12/2026, 09:54 PM
Read Full TranscriptEarnings
Latest Release
Aug 12, 2026
EPS / Forecast
-- / -0.14
Revenue / Forecast
-- / 9M
Compare FYB to Peers and Sector
Metrics to compare | FYB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFYBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.8x | 18.6x | −0.4x | |
PEG Ratio | - | 0.01 | 0.00 | |
Price/Book | 0.9x | 3.1x | 2.6x | |
Price / LTM Sales | 6.3x | 3.8x | 3.1x | |
Upside (Analyst Target) | 97.4% | 27.3% | 47.5% | |
Fair Value Upside | Unlock | 10.2% | 5.9% | Unlock |
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, asthma, hodgkin’s lymphoma, urothelial carcinomas, tumors in the head and neck area, sinusitis with nasal polyps area, other tumor and genetic diseases; and FYB208 and FYB209 that is indicated for immunology areas. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Formycon (FYB) Stock Price Today?
The Formycon stock price today is 18.50 EUR.
What Stock Exchange Does Formycon Trade On?
Formycon is listed and trades on the Frankfurt Stock Exchange.
What Is the Stock Symbol for Formycon?
The stock symbol for Formycon is "FYB."
What Is the Formycon Market Cap?
As of today, Formycon market cap is 326.95M EUR.
What Is Formycon's Earnings Per Share (TTM)?
The Formycon EPS (TTM) is -3.22.
When Is the Next Formycon Earnings Date?
Formycon will release its next earnings report on Nov 12, 2026.
From a Technical Analysis Perspective, Is FYB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Formycon Stock Split?
Formycon has split 3 times.
How Many Employees Does Formycon Have?
Formycon has 203 employees.
What is the current trading status of Formycon (FYB)?
As of Aug 13, 2026, Formycon (FYB) is trading at a price of 18.50 EUR, with a previous close of 19.16 EUR. The stock has fluctuated within a day range of 18.50 EUR to 19.40 EUR, while its 52-week range spans from 15.80 EUR to 26.95 EUR.
What Is Formycon (FYB) Price Target According to Analysts?
The average 12-month price target for Formycon is 39.67 EUR, with a high estimate of 51 EUR and a low estimate of 30 EUR. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +114.41% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.